<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">S. Roels</style></author><author><style face="normal" font="default" size="100%">Tilmant, K</style></author><author><style face="normal" font="default" size="100%">Van Daele, A</style></author><author><style face="normal" font="default" size="100%">Van Marck, E</style></author><author><style face="normal" font="default" size="100%">Ducatelle, R</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Proliferation, DNA ploidy, p53 overexpression and nuclear DNA fragmentation in six equine melanocytic tumours.</style></title><secondary-title><style face="normal" font="default" size="100%">J Vet Med A Physiol Pathol Clin Med</style></secondary-title><alt-title><style face="normal" font="default" size="100%">J Vet Med A Physiol Pathol Clin Med</style></alt-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Animals</style></keyword><keyword><style  face="normal" font="default" size="100%">Apoptosis</style></keyword><keyword><style  face="normal" font="default" size="100%">Biopsy</style></keyword><keyword><style  face="normal" font="default" size="100%">Coloring Agents</style></keyword><keyword><style  face="normal" font="default" size="100%">DNA Fragmentation</style></keyword><keyword><style  face="normal" font="default" size="100%">Female</style></keyword><keyword><style  face="normal" font="default" size="100%">Gene Expression Regulation, Neoplastic</style></keyword><keyword><style  face="normal" font="default" size="100%">Genes, p53</style></keyword><keyword><style  face="normal" font="default" size="100%">Horse Diseases</style></keyword><keyword><style  face="normal" font="default" size="100%">Horses</style></keyword><keyword><style  face="normal" font="default" size="100%">Image Processing, Computer-Assisted</style></keyword><keyword><style  face="normal" font="default" size="100%">immunohistochemistry</style></keyword><keyword><style  face="normal" font="default" size="100%">In Situ Nick-End Labeling</style></keyword><keyword><style  face="normal" font="default" size="100%">Ki-67 Antigen</style></keyword><keyword><style  face="normal" font="default" size="100%">Male</style></keyword><keyword><style  face="normal" font="default" size="100%">Melanins</style></keyword><keyword><style  face="normal" font="default" size="100%">Melanoma</style></keyword><keyword><style  face="normal" font="default" size="100%">Ploidies</style></keyword><keyword><style  face="normal" font="default" size="100%">Proliferating Cell Nuclear Antigen</style></keyword><keyword><style  face="normal" font="default" size="100%">Rosaniline Dyes</style></keyword><keyword><style  face="normal" font="default" size="100%">Skin Neoplasms</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2000</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2000 Sep</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">47</style></volume><pages><style face="normal" font="default" size="100%">439-48</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Melanocytic tumours are a well-known clinical and pathological entity in horses, but further phenotypic characterization of these tumours is lacking. Six melanocytic tumours from five horses (two metastatic and four benign) were examined by Ki67, PCNA and p53 immunostaining, DNA nick end labelling (Tunel) and Feulgen staining. The stainings were evaluated using quantitative image analysis. The resulting parameters of growth fraction (Ki67), S-phase index (PCNA), p53 index, apoptotic index, DNA index, nuclear diameter, ploidy balance, proliferation index (Feulgen) and hyperploidy were analysed. The metastatic melanomas showed overexpression of p53 in a large portion of the cells. Apoptosis was also found in the metastatic melanomas. No differences were found in growth fraction, S-phase index (PCNA) nor in DNA configuration between the metastatic and the benign tumours. No immunohistochemical evidence of mutant p53 could be found in the tumours. In conclusion, melanocytic tumours in horses seem to have different phenotypic characteristics in comparison with melanocytic tumours in dogs, cats and humans, especially with respect to proliferative activity of the benign tumours. Therefore, markers put forward in these other species for predicting the clinical behaviour of the melanomas seem to be of no value in the horse. Moreover, quantitative DNA changes or p53 mutations do not seem to be involved in tumourogenesis in these cases.&lt;/p&gt;</style></abstract><issue><style face="normal" font="default" size="100%">7</style></issue><custom1><style face="normal" font="default" size="100%">http://www.ncbi.nlm.nih.gov/pubmed/11076465?dopt=Abstract</style></custom1></record></records></xml>